Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown
Aybintio Joins Amgen And Pfizer Avastin Rivals Ready For Expiry
Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.
You may also be interested in...
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.